The pathway through LC-MS method development: in-house or ready-to-use kit-based methods?
-
Caroline Le Goff
,
Jordi Farre-Segura
Abstract
Historically, the determination of low concentration analytes was initially made possible by the development of rapid and easy-to-perform immunoassays (IAs). Unfortunately, typical problems inherent to IA technologies rapidly appeared (e.g. elevated cost, cross-reactivity, lot-to-lot variability, etc.). In turn, liquid chromatography tandem mass spectrometry (LC-MS/MS) methods are sensitive and specific enough for such analyses. Therefore, they would seem to be the most promising candidates to replace IAs. There are two main choices when implementing a new LC-MS/MS method in a clinical laboratory: (1) Developing an in-house method or (2) purchasing ready-to-use kits. In this paper, we discuss some of the respective advantages, disadvantages and mandatory requirements of each choice. Additionally, we also share our experiences when developing an in-house method for cortisol determination and the implementation of an “ready-to-use” (RTU) kit for steroids analysis.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Vogeser M, Seger C. LC–MS/MS in clinical chemistry. J Chromatogr B 2012;883–884:1–2.10.1016/j.jchromb.2012.01.001Suche in Google Scholar PubMed
2. Carvalho VM. The coming of age of liquid chromatography coupled to tandem mass spectrometry in the endocrinology laboratory. J Chromatogr B Anal Technol Biomed Life Sci 2012;883–884:50–8.10.1016/j.jchromb.2011.08.027Suche in Google Scholar PubMed
3. Hunter WM, Budd PS. Circulating antibodies to ovine and bovine immunoglobin in healthy subjects: a hazard for immunoassays. Lancet 1980;316:1136.10.1016/S0140-6736(80)92565-9Suche in Google Scholar
4. Al-Dujaili EA, Edwards CR. Development and application of a simple radioimmunoassay for urinary aldosterone. Clin Chim Acta 1981;116:277–87.10.1016/0009-8981(81)90047-4Suche in Google Scholar PubMed
5. Cavalier E, Lukas P, Bekaert A-C, Peeters S, Le Goff C, Yayo E, et al. Analytical and clinical evaluation of the new Fujirebio Lumipulse® G non-competitive assay for 25(OH)-Vitamin D and three immunoassays for 25(OH)D in healthy subjects, osteoporotic patients, third trimester pregnant women, healthy African subjects, hemodialyzed and intensive care patients. Clin Chem Lab Med 2016;54:1347–55.10.1515/cclm-2015-0923Suche in Google Scholar PubMed
6. Cavalier E, Rousselle O, Ferrante N, Carlisi A, Le Goff C, Souberbielle J-C. Technical and clinical evaluation of the VITROS® immunodiagnostic products 25-OH vitamin D total assay – comparison with marketed automated immunoassays and a liquid chromatography tandem mass spectrometry method. Clin Chem Lab Med 2013;51:1983–9.10.1515/cclm-2013-0138Suche in Google Scholar PubMed
7. Dorrian CA, Toole BJ, Alvarez-Madrazo S, Kelly A, Connell JM, Wallace AM. A screening procedure for primary aldosteronism based on the Diasorin Laision automated chemilumuniscent immunoassay for direct renin. Ann Clin Biochem 2010;47:195–9.10.1258/acb.2010.009230Suche in Google Scholar PubMed
8. Horton R, Hawks D, Lobo R. 3a, 17f-androstanediol glucuronide in plasma. A marker of androgen action in idiopathic hirsutism. J Clin Invest 1982;69:1203–6.10.1172/JCI110558Suche in Google Scholar
9. Wu AH, French D. Implementation of liquid chromatography/mass spectrometry into the clinical laboratory. Clin Chim Acta 2013;420:4–10.10.1016/j.cca.2012.10.026Suche in Google Scholar PubMed
10. Meunier C, Blondelle D, Faure P, Baguet J-P, Le Goff C, Chabre O, et al. Development and validation of a method using supported liquid extraction for aldosterone determination in human plasma by LC-MS/MS. Clin Chim Acta 2015;447:8–15.10.1016/j.cca.2015.05.007Suche in Google Scholar PubMed
11. Le Goff CM, Gonzalez-Antuña A, Peeters SD, Fabregat-Cabello N, Van Der Gugten JG, Vroonen L, et al. Migration from RIA to LC-MS/MS for aldosterone determination: Implications for clinical practice and determination of plasma and urine reference range intervals in a cohort of healthy Belgian subjects. Clin Mass Spectrom 2018;9:7–17.10.1016/j.clinms.2018.06.002Suche in Google Scholar
12. Perich C, Minchinela J, Ricós C, Fernández-Calle P, Alvarez V, Doménech MV, et al. Biological variation database: structure and criteria used for generation and update. Clin Chem Lab Med 2015;53:299–305.10.1515/cclm-2014-0739Suche in Google Scholar PubMed
13. Fraser CG, Petersen PH. Analytical performance characteristics should be judged against objective quality specifications. Clin Chem 1999;45:321–3.10.1093/clinchem/45.3.321Suche in Google Scholar
14. Kushnir MM, Rockwood AL, Bergquist J, Varshavsky M, Roberts WL, Yue B, et al. High-sensitivity tandem mass spectrometry assay for serum estrone and estradiol. Am J Clin Pathol 2008;129:530–9.10.1309/LC03BHQ5XJPJYEKGSuche in Google Scholar PubMed
15. Shiraishi S, Lee PW, Leung A, Goh VH, Swerdloff RS, Wang C. Simultaneous measurement of serum testosterone and dihydrotestosterone by liquid chromatography-tandem mass spectrometry. Clin Chem 2008;54:1855–63.10.1373/clinchem.2008.103846Suche in Google Scholar PubMed
16. Lynch KL. CLSI C62-A: A new standard for clinical mass spectrometry. Clin Chem 2016;62:24–9.10.1373/clinchem.2015.238626Suche in Google Scholar PubMed
17. Van den Ouweland JM, Kema IP. The role of liquid chromatography-tandem mass spectrometry in the clinical laboratory. J Chromatogr B Anal Technol Biomed Life Sci 2012;883–884:18–32.10.1016/j.jchromb.2011.11.044Suche in Google Scholar PubMed
18. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003;75:3019–30.10.1021/ac020361sSuche in Google Scholar PubMed
19. Keevil BG. LC–MS/MS analysis of steroids in the clinical laboratory. Clin Biochem 2016;49:989–97.10.1016/j.clinbiochem.2016.04.009Suche in Google Scholar PubMed
20. Vogeser M. Pitfalls associated with the use of liquid chromatography-tandem mass spectrometry in the clinical laboratory. Clin Chem 2008;54:1406–8.10.1373/clinchem.2009.138602Suche in Google Scholar PubMed
21. Carvalho VM, Nakamura OH, Vieira JG. Simultaneous quantitation of seven endogenous C-21 adrenal steroids by liquid chromatography tandem mass spectrometry in human serum. J Chromatogr B Anal Technol Biomed Life Sci 2008;872:154–61.10.1016/j.jchromb.2008.07.035Suche in Google Scholar PubMed
22. Solberg HE. The IFCC recommendation on estimation of reference intervals. The RefVal program. Clin Chem Lab Med 2004;42:710–4.10.1515/CCLM.2004.121Suche in Google Scholar PubMed
Supplementary Material
The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2019-0916).
©2020 Walter de Gruyter GmbH, Berlin/Boston
Artikel in diesem Heft
- Frontmatter
- Editorial
- Advancements in mass spectrometry as a tool for clinical analysis: part II
- Quantitative protein assessment
- Complexity, cost, and content – three important factors for translation of clinical protein mass spectrometry tests, and the case for apolipoprotein C-III proteoform testing
- Vedolizumab quantitation using high-resolution accurate mass-mass spectrometry middle-up protein subunit: method validation
- Development and evaluation of an element-tagged immunoassay coupled with inductively coupled plasma mass spectrometry detection: can we apply the new assay in the clinical laboratory?
- MALDI-MS for the clinic
- Matrix-assisted laser desorption ionisation (MALDI) mass spectrometry (MS): basics and clinical applications
- Clinical use of mass spectrometry (imaging) for hard tissue analysis in abnormal fracture healing
- Cellular resolution in clinical MALDI mass spectrometry imaging: the latest advancements and current challenges
- Bacterial identification by lipid profiling using liquid atmospheric pressure matrix-assisted laser desorption/ionization mass spectrometry
- Clinical application of ’omics technologies
- Individualized metabolomics: opportunities and challenges
- Diagnostic amyloid proteomics: experience of the UK National Amyloidosis Centre
- The “olfactory fingerprint”: can diagnostics be improved by combining canine and digital noses?
- Peptidomic and proteomic analysis of stool for diagnosing IBD and deciphering disease pathogenesis
- The influence of hypoxia on the prostate cancer proteome
- Laboratory automation and kit-based approaches
- Mass spectrometry and total laboratory automation: opportunities and drawbacks
- The pathway through LC-MS method development: in-house or ready-to-use kit-based methods?
- Evaluation of the 25-hydroxy vitamin D assay on a fully automated liquid chromatography mass spectrometry system, the Thermo Scientific Cascadion SM Clinical Analyzer with the Cascadion 25-hydroxy vitamin D assay in a routine clinical laboratory
Artikel in diesem Heft
- Frontmatter
- Editorial
- Advancements in mass spectrometry as a tool for clinical analysis: part II
- Quantitative protein assessment
- Complexity, cost, and content – three important factors for translation of clinical protein mass spectrometry tests, and the case for apolipoprotein C-III proteoform testing
- Vedolizumab quantitation using high-resolution accurate mass-mass spectrometry middle-up protein subunit: method validation
- Development and evaluation of an element-tagged immunoassay coupled with inductively coupled plasma mass spectrometry detection: can we apply the new assay in the clinical laboratory?
- MALDI-MS for the clinic
- Matrix-assisted laser desorption ionisation (MALDI) mass spectrometry (MS): basics and clinical applications
- Clinical use of mass spectrometry (imaging) for hard tissue analysis in abnormal fracture healing
- Cellular resolution in clinical MALDI mass spectrometry imaging: the latest advancements and current challenges
- Bacterial identification by lipid profiling using liquid atmospheric pressure matrix-assisted laser desorption/ionization mass spectrometry
- Clinical application of ’omics technologies
- Individualized metabolomics: opportunities and challenges
- Diagnostic amyloid proteomics: experience of the UK National Amyloidosis Centre
- The “olfactory fingerprint”: can diagnostics be improved by combining canine and digital noses?
- Peptidomic and proteomic analysis of stool for diagnosing IBD and deciphering disease pathogenesis
- The influence of hypoxia on the prostate cancer proteome
- Laboratory automation and kit-based approaches
- Mass spectrometry and total laboratory automation: opportunities and drawbacks
- The pathway through LC-MS method development: in-house or ready-to-use kit-based methods?
- Evaluation of the 25-hydroxy vitamin D assay on a fully automated liquid chromatography mass spectrometry system, the Thermo Scientific Cascadion SM Clinical Analyzer with the Cascadion 25-hydroxy vitamin D assay in a routine clinical laboratory
